Elutia (NASDAQ:ELUT) reported second-quarter 2026 net sales of $2.4 million, down from $2.7 million a year earlier, while outlining plans to concentrate its resources on the development and commercialization of its NXT-41x drug-eluting surgical matrix for plastic and reconstructive surgery. President and CEO Randy Mills said the company secured up to $26 million in additional [...]
Elutia Q2 Earnings Call Highlights
